Literature DB >> 10545023

Antiangiogenic and antitumor effects of 14-membered ring macrolides on mouse B16 melanoma cells.

J Yatsunami1, Y Fukuno, M Nagata, M Tominaga, S Aoki, N Tsuruta, M Kawashima, S Taniguchi, S Hayashi.   

Abstract

We examined the effects of macrolide antibiotics on tumor angiogenesis, tumor growth and metastasis in the B 16BL6 mouse melanoma and C57BL mouse system. Two 14-membered ring macrolide antibiotics, roxithromycin and clarithromycin, significantly reduced the dense capillary network area in a mouse dorsal air sac angiogenesis model, whereas a 15-membered ring macrolide, azithromycin, and a 16-membered ring macrolide, josamycin, did not show any inhibitory effect on angiogenesis at the same dose. Intraperitoneal administration of roxithromycin and clarithromycin at 50 mg/kg/day reduced the tumor size of B 16BL6 melanoma to about 41% and 56%, respectively, of that of the control, and significantly suppressed pulmonary metastasis of B16BL6 cells in a spontaneous system. Azithromycin and josamycin, on the other hand, did not inhibit tumor growth or pulmonary metastasis of B16BL6 cells. Immunohistochemistry revealed that roxithromycin and clarithromycin reduced the tumor vascularity and increased apoptosis of the tumor cells in vivo. These results suggest that 14-membered ring macrolides have antiangiogenic and antitumor effects and might have possible therapeutic applications.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10545023     DOI: 10.1023/a:1006605725619

Source DB:  PubMed          Journal:  Clin Exp Metastasis        ISSN: 0262-0898            Impact factor:   5.150


  30 in total

1.  Captopril inhibits angiogenesis and slows the growth of experimental tumors in rats.

Authors:  O V Volpert; W F Ward; M W Lingen; L Chesler; D B Solt; M D Johnson; A Molteni; P J Polverini; N P Bouck
Journal:  J Clin Invest       Date:  1996-08-01       Impact factor: 14.808

2.  Therapeutic effect of clarithromycin on a transplanted tumor in rats.

Authors:  K Sassa; Y Mizushima; T Fujishita; R Oosaki; M Kobayashi
Journal:  Antimicrob Agents Chemother       Date:  1999-01       Impact factor: 5.191

Review 3.  Antibacterial therapy: problems and promises, Part II.

Authors:  H C Neu
Journal:  Hosp Pract (Off Ed)       Date:  1990-06-15

4.  Interleukin-8 participates in angiogenesis in non-small cell, but not small cell carcinoma of the lung.

Authors:  J Yatsunami; N Tsuruta; K Ogata; K Wakamatsu; K Takayama; M Kawasaki; Y Nakanishi; N Hara; S Hayashi
Journal:  Cancer Lett       Date:  1997-11-25       Impact factor: 8.679

5.  Endostatin: an endogenous inhibitor of angiogenesis and tumor growth.

Authors:  M S O'Reilly; T Boehm; Y Shing; N Fukai; G Vasios; W S Lane; E Flynn; J R Birkhead; B R Olsen; J Folkman
Journal:  Cell       Date:  1997-01-24       Impact factor: 41.582

6.  Inhibitory effects of roxithromycin on tumor angiogenesis, growth and metastasis of mouse B16 melanoma cells.

Authors:  J Yatsunami; N Tsuruta; Y Fukuno; M Kawashima; S Taniguchi; S Hayashi
Journal:  Clin Exp Metastasis       Date:  1999-03       Impact factor: 5.150

7.  Angiogenesis inhibition by minocycline.

Authors:  R J Tamargo; R A Bok; H Brem
Journal:  Cancer Res       Date:  1991-01-15       Impact factor: 12.701

8.  A randomized trial of clarithromycin as prophylaxis against disseminated Mycobacterium avium complex infection in patients with advanced acquired immunodeficiency syndrome.

Authors:  M Pierce; S Crampton; D Henry; L Heifets; A LaMarca; M Montecalvo; G P Wormser; H Jablonowski; J Jemsek; M Cynamon; B G Yangco; G Notario; J C Craft
Journal:  N Engl J Med       Date:  1996-08-08       Impact factor: 91.245

9.  Epithelial-neutrophil activating peptide (ENA-78) is an important angiogenic factor in non-small cell lung cancer.

Authors:  D A Arenberg; M P Keane; B DiGiovine; S L Kunkel; S B Morris; Y Y Xue; M D Burdick; M C Glass; M D Iannettoni; R M Strieter
Journal:  J Clin Invest       Date:  1998-08-01       Impact factor: 14.808

10.  Inhibition of tumor growth and neovascularization by an anti-gastric ulcer agent, irsogladine.

Authors:  M Ono; N Kawahara; D Goto; Y Wakabayashi; S Ushiro; S Yoshida; H Izumi; M Kuwano; Y Sato
Journal:  Cancer Res       Date:  1996-04-01       Impact factor: 12.701

View more
  12 in total

Review 1.  Immuno-modulation and anti-inflammatory benefits of antibiotics: the example of tilmicosin.

Authors:  André G Buret
Journal:  Can J Vet Res       Date:  2010-01       Impact factor: 1.310

2.  Macrolide antibiotics differentially influence human HepG2 cytotoxicity and modulate intrinsic/extrinsic apoptotic pathways in rat hepatocellular carcinoma model.

Authors:  Nagwa I Abdel-Hamid; Mona F El-Azab; Yasser M Moustafa
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2017-01-09       Impact factor: 3.000

Review 3.  Mechanisms of action and clinical application of macrolides as immunomodulatory medications.

Authors:  Soichiro Kanoh; Bruce K Rubin
Journal:  Clin Microbiol Rev       Date:  2010-07       Impact factor: 26.132

Review 4.  Immunomodulatory effects of macrolide antibiotics in respiratory disease: therapeutic implications for asthma and cystic fibrosis.

Authors:  Sanjiv Sharma; Adam Jaffe; Garth Dixon
Journal:  Paediatr Drugs       Date:  2007       Impact factor: 3.022

5.  Anti-Inflammatory benefits of antibiotic-induced neutrophil apoptosis: tulathromycin induces caspase-3-dependent neutrophil programmed cell death and inhibits NF-kappaB signaling and CXCL8 transcription.

Authors:  Carrie D Fischer; Jennifer K Beatty; Cheryl G Zvaigzne; Douglas W Morck; Merlyn J Lucas; A G Buret
Journal:  Antimicrob Agents Chemother       Date:  2010-10-18       Impact factor: 5.191

6.  Effect of Antimicrobial Prophylaxis on Corynebacterium bovis Infection and the Skin Microbiome of Immunodeficient Mice.

Authors:  Christopher A Manuel; Linda K Johnson; Uma Pugazhenthi; Derek L Fong; Michaelk Fink; Lauren M Habenicht; Jori K Leszczynski; I R Diana; Michael J Schurr; Daniel N Frank
Journal:  Comp Med       Date:  2022-04-04       Impact factor: 1.565

7.  Repurposing Drugs in Oncology (ReDO)-clarithromycin as an anti-cancer agent.

Authors:  An Mt Van Nuffel; Vidula Sukhatme; Pan Pantziarka; Lydie Meheus; Vikas P Sukhatme; Gauthier Bouche
Journal:  Ecancermedicalscience       Date:  2015-02-24

8.  Clarithromycin expands CD11b+Gr-1+ cells via the STAT3/Bv8 axis to ameliorate lethal endotoxic shock and post-influenza bacterial pneumonia.

Authors:  Ho Namkoong; Makoto Ishii; Hideki Fujii; Kazuma Yagi; Takahiro Asami; Takanori Asakura; Shoji Suzuki; Ahmed E Hegab; Hirofumi Kamata; Sadatomo Tasaka; Koji Atarashi; Nobuhiro Nakamoto; Satoshi Iwata; Kenya Honda; Takanori Kanai; Naoki Hasegawa; Shigeo Koyasu; Tomoko Betsuyaku
Journal:  PLoS Pathog       Date:  2018-04-05       Impact factor: 6.823

9.  Azithromycin synergistically enhances anti-proliferative activity of vincristine in cervical and gastric cancer cells.

Authors:  Xuezhang Zhou; Yuyan Zhang; Yong Li; Xiujing Hao; Xiaoming Liu; Yujiong Wang
Journal:  Cancers (Basel)       Date:  2012-12-04       Impact factor: 6.639

10.  Development of Novel Erythromycin Derivatives with Inhibitory Activity against Proliferation of Tumor Cells.

Authors:  Lan Wu; Kai Bao; Rui Song; Defa Wang; Lei Zhang; Weiyun Wang; Weige Zhang; Wen Bin
Journal:  PLoS One       Date:  2016-07-22       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.